Alyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Alyeska Investment Group L.P. reduced its shares in Vaxcyte, Inc. by 16.7%, now holding a total of 164,640 shares worth approximately $6.2 million.
• Other institutional investors significantly increased their positions in Vaxcyte, with RA Capital Management boosting its stake by 40.3% and Wellington Management increasing theirs by 44.4% during the first quarter.
• Vaxcyte currently maintains an average rating of "Buy" from analysts with a price target of $130, despite reporting a quarterly loss of ($1.22) EPS, missing expectations.

Alyeska Investment Group L.P. trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 16.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 164,640 shares of the company's stock after selling 32,945 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.13% of Vaxcyte worth $6,217,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. boosted its holdings in shares of Vaxcyte by 40.3% in the 1st quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company's stock valued at $460,262,000 after buying an additional 3,499,959 shares during the last quarter. Wellington Management Group LLP raised its position in Vaxcyte by 44.4% during the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company's stock worth $242,303,000 after acquiring an additional 1,972,918 shares in the last quarter. Baker BROS. Advisors LP raised its position in Vaxcyte by 1,211.0% during the first quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company's stock worth $24,200,000 after acquiring an additional 592,000 shares in the last quarter. Nuveen LLC acquired a new stake in Vaxcyte in the first quarter valued at $20,988,000. Finally, Paradigm Biocapital Advisors LP grew its position in shares of Vaxcyte by 57.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after acquiring an additional 518,255 shares during the period. Institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

Vaxcyte stock traded up $1.06 during mid-day trading on Thursday, hitting $33.06. 1,477,499 shares of the company's stock traded hands, compared to its average volume of 1,400,220. The firm has a 50 day simple moving average of $33.18 and a two-hundred day simple moving average of $39.61. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The stock has a market cap of $4.29 billion, a price-to-earnings ratio of -8.04 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the previous year, the business posted ($1.10) EPS. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $121.75.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.